Platelet-derived growth factor-BB attenuates titanium-particle-induced osteolysis in vivo. (1st November 2016)

• Record Type: Journal Article
• Authors: Ye, Chenyi; Zhang, Wei; Jiang, Shuai; Yu, Yuanbin; Zhou, Xiaoyu; Zhu, Ling; Xue, Deting; He, Rongxin
• Is Part Of: Growth factors. Volume 34:Number 5/6(2016:Oct.)
• Page Start: 177
• Page End: 186
• Publication Date: 2016-11-01
• Subjects: Periprosthetic osteolysis -- platelet-derived growth factor -- osteogenesis -- angiogenesis; Growth factors -- Periodicals; Physiology -- Periodicals; 611
• DOI: 10.1080/08977194.2016.1240680
• Languages: English
• ISSNs: 0897-7194

Abstract

Abstract: Inflammation and osteoclastogenesis play critical roles in wear-particle-induced periprosthetic osteolysis (WPO). Platelet-derived growth factor-BB (PDGF-BB) could promote osteogenesis and inhibit inflammatory response. The aim of this study was to investigate the impact of PDGF-BB on WPO. Mice were divided into four groups, namely, sham, vehicle, low-, and high-dose PDGF-BB groups. Mice in the rhPDGF-BB groups were treated with PDGF-BB at 0.25 or 1 mg/ml/kg/day. Mice in the sham and vehicle groups received PBS daily. Two weeks after surgery, calvariae were harvested. Immunohistochemical analysis and μ-CT showed that PDGF-BB significantly reduced osteoclast formation and bone resorption. ELISA showed that rhPDGF-BB decreased the secretion of TNF-α, IL-1β, and IL-6. Western blotting revealed that rhPDGF-BB stimulated the expression of osteocalcin and osteoprotegerin. Furthermore, more VEGF and CD31 proteins were observed due to PDGF-BB by immunofluorescence. In conclusion, these findings suggest that rhPDGF-BB represents a potential treatment for WPO.